O	0	11	Combination
O	12	14	of
B-intervention	15	23	inositol
I-intervention	24	27	and
I-intervention	28	33	alpha
I-intervention	34	40	lipoic
I-intervention	41	45	acid
O	46	48	in
O	49	58	metabolic
O	59	67	syndrome
O	67	68	-
O	68	76	affected
O	77	82	women
O	82	83	:
O	84	85	a
O	86	96	randomized
O	97	104	placebo
O	104	105	-
O	105	115	controlled
O	116	121	trial
O	121	122	.

O	123	131	Inositol
O	132	135	has
O	136	140	been
O	141	149	reported
O	150	152	to
O	153	160	improve
O	161	168	insulin
O	169	180	sensitivity
O	181	186	since
O	187	189	it
O	190	195	works
O	196	198	as
O	199	200	a
O	201	207	second
O	208	217	messenger
O	218	227	achieving
O	228	235	insulin
O	235	236	-
O	236	240	like
O	241	248	effects
O	249	251	on
O	252	261	metabolic
O	262	269	enzymes
O	269	270	.

O	271	274	The
O	275	278	aim
O	279	281	of
O	282	286	this
O	287	292	study
O	293	296	was
O	297	299	to
O	300	308	evaluate
O	309	312	the
O	313	321	inositol
O	322	325	and
O	326	331	alpha
O	332	338	lipoic
O	339	343	acid
O	344	355	combination
O	356	369	effectiveness
O	370	372	on
O	373	382	metabolic
O	383	391	syndrome
O	392	400	features
O	401	403	in
O	404	418	postmenopausal
O	419	424	women
O	425	427	at
O	428	432	risk
O	433	435	of
O	436	442	breast
O	443	449	cancer
O	449	450	.

O	451	452	A
O	453	456	six
O	456	457	-
O	457	462	month
O	463	474	prospective
O	474	475	,
O	476	486	randomized
O	487	494	placebo
O	494	495	-
O	495	505	controlled
O	506	511	trial
O	512	515	was
O	516	523	carried
O	524	527	out
O	528	530	on
O	531	532	a
O	533	538	total
O	539	541	of
B-total-participants	542	545	155
B-eligibility	546	560	postmenopausal
I-eligibility	561	566	women
I-eligibility	567	575	affected
I-eligibility	576	578	by
I-eligibility	579	588	metabolic
I-eligibility	589	597	syndrome
I-eligibility	598	600	at
I-eligibility	601	605	risk
I-eligibility	606	608	of
I-eligibility	609	615	breast
I-eligibility	616	622	cancer
I-eligibility	622	623	,
O	624	627	the
O	628	636	INOSIDEX
O	637	642	trial
O	642	643	.

O	644	647	All
O	648	653	women
O	654	658	were
O	659	664	asked
O	665	667	to
O	668	674	follow
O	675	676	a
O	677	680	low
O	680	681	-
O	681	688	calorie
O	689	693	diet
O	694	697	and
O	698	702	were
O	703	711	assigned
O	712	720	randomly
O	721	723	to
O	724	729	daily
O	730	741	consumption
O	742	744	of
O	745	746	a
O	747	758	combination
O	759	761	of
O	762	770	inositol
O	771	774	and
O	775	780	alpha
O	781	787	lipoic
O	788	792	acid
O	793	794	(
B-intervention-participants	794	796	77
O	797	800	pts
O	800	801	)
O	802	804	or
B-control	805	812	placebo
O	813	814	(
B-control-participants	814	816	78
O	817	820	pts
O	820	821	)
O	822	825	for
O	826	829	six
O	830	836	months
O	836	837	.

O	838	845	Primary
O	846	854	outcomes
O	855	857	we
O	858	864	wanted
O	865	867	to
O	868	875	achieve
O	876	880	were
O	881	885	both
B-outcome-Measure	886	895	reduction
I-outcome-Measure	896	898	of
I-outcome-Measure	899	903	more
I-outcome-Measure	904	908	than
I-outcome-Measure	909	911	20
I-outcome-Measure	911	912	%
I-outcome-Measure	913	915	of
I-outcome-Measure	916	919	the
I-outcome-Measure	920	924	HOMA
I-outcome-Measure	924	925	-
I-outcome-Measure	925	927	IR
I-outcome-Measure	928	933	index
I-outcome-Measure	934	937	and
I-outcome-Measure	938	940	of
I-outcome-Measure	941	954	triglycerides
I-outcome-Measure	955	960	serum
I-outcome-Measure	961	967	levels
O	967	968	.

O	969	978	Secondary
O	979	987	outcomes
O	988	996	expected
O	997	1001	were
O	1002	1006	both
O	1007	1010	the
B-outcome-Measure	1011	1022	improvement
I-outcome-Measure	1023	1025	of
I-outcome-Measure	1026	1030	high
I-outcome-Measure	1030	1031	-
I-outcome-Measure	1031	1038	density
I-outcome-Measure	1039	1050	lipoprotein
I-outcome-Measure	1051	1062	cholesterol
I-outcome-Measure	1063	1069	levels
O	1070	1073	and
O	1074	1077	the
B-outcome-Measure	1078	1087	reduction
I-outcome-Measure	1088	1090	of
I-outcome-Measure	1091	1105	anthropometric
I-outcome-Measure	1106	1114	features
O	1115	1119	such
O	1120	1122	as
O	1123	1127	body
O	1128	1132	mass
O	1133	1138	index
O	1139	1142	and
O	1143	1148	waist
O	1148	1149	-
O	1149	1152	hip
O	1153	1158	ratio
O	1158	1159	.

O	1160	1161	A
O	1162	1173	significant
B-outcome	1174	1178	HOMA
I-outcome	1178	1179	-
I-outcome	1179	1181	IR
I-outcome	1182	1191	reduction
O	1192	1194	of
O	1195	1199	more
O	1200	1204	than
O	1205	1207	20
O	1207	1208	%
O	1209	1212	was
O	1213	1222	evidenced
O	1223	1225	in
O	1226	1228	66
O	1228	1229	.
O	1229	1230	7
O	1230	1231	%
O	1232	1233	(
O	1233	1234	P
O	1235	1236	<
O	1236	1237	0
O	1237	1238	.
O	1238	1242	0001
O	1242	1243	)
O	1244	1246	of
O	1247	1255	patients
O	1255	1256	,
O	1257	1267	associated
O	1268	1272	with
O	1273	1274	a
B-outcome	1275	1280	serum
I-outcome	1281	1288	insulin
I-outcome	1289	1294	level
O	1295	1303	decrease
O	1304	1306	in
O	1307	1309	89
O	1309	1310	.
O	1310	1311	3
O	1311	1312	%
O	1313	1314	(
O	1314	1315	P
O	1316	1317	<
O	1317	1318	0
O	1318	1319	.
O	1319	1323	0000
O	1323	1324	)
O	1324	1325	.

O	1326	1327	A
O	1328	1336	decrease
O	1337	1339	in
B-outcome	1340	1353	triglycerides
O	1354	1357	was
O	1358	1367	evidenced
O	1368	1370	in
O	1371	1373	43
O	1373	1374	.
O	1374	1375	2
O	1375	1376	%
O	1377	1379	of
O	1380	1388	patients
O	1389	1398	consuming
O	1399	1402	the
O	1403	1413	supplement
O	1414	1415	(
O	1415	1416	P
O	1417	1418	<
O	1418	1419	0
O	1419	1420	.
O	1420	1424	0001
O	1424	1425	)
O	1425	1426	.

O	1427	1429	An
O	1430	1438	increase
O	1439	1441	in
B-outcome	1442	1445	HDL
I-outcome	1446	1457	cholesterol
O	1458	1459	(
O	1459	1461	48
O	1461	1462	.
O	1462	1463	6
O	1463	1464	%
O	1464	1465	)
O	1466	1469	was
O	1470	1475	found
O	1476	1478	in
O	1479	1482	the
O	1483	1488	group
O	1489	1498	consuming
O	1499	1507	inositol
O	1508	1512	with
O	1513	1520	respect
O	1521	1523	to
O	1524	1527	the
O	1528	1535	placebo
O	1536	1541	group
O	1541	1542	.

O	1543	1544	A
O	1545	1554	reduction
O	1555	1557	in
B-outcome	1558	1563	waist
I-outcome	1564	1577	circumference
O	1578	1581	and
B-outcome	1582	1587	waist
I-outcome	1587	1588	-
I-outcome	1588	1591	hip
I-outcome	1592	1597	ratio
O	1598	1601	was
O	1602	1607	found
O	1608	1610	in
O	1611	1614	the
O	1615	1622	treated
O	1623	1628	group
O	1629	1633	with
O	1634	1641	respect
O	1642	1644	to
O	1645	1648	the
O	1649	1656	placebo
O	1657	1662	group
O	1662	1663	.

O	1664	1672	Inositol
O	1673	1681	combined
O	1682	1686	with
O	1687	1692	alpha
O	1693	1699	lipoic
O	1700	1704	acid
O	1705	1708	can
O	1709	1711	be
O	1712	1716	used
O	1717	1719	as
O	1720	1721	a
O	1722	1729	dietary
O	1730	1740	supplement
O	1741	1743	in
O	1744	1751	insulin
O	1751	1752	-
O	1752	1761	resistant
O	1762	1770	patients
O	1771	1773	in
O	1774	1779	order
O	1780	1782	to
O	1783	1791	increase
O	1792	1797	their
O	1798	1805	insulin
O	1806	1819	sensitiveness
O	1819	1820	.

O	1821	1826	Daily
O	1827	1838	consumption
O	1839	1841	of
O	1842	1850	inositol
O	1851	1859	combined
O	1860	1864	with
O	1865	1870	alpha
O	1871	1877	lipoic
O	1878	1882	acid
O	1883	1886	has
O	1887	1888	a
O	1889	1900	significant
O	1901	1908	bearing
O	1909	1911	on
O	1912	1921	metabolic
O	1922	1930	syndrome
O	1930	1931	.

O	1932	1934	As
O	1935	1944	metabolic
O	1945	1953	syndrome
O	1954	1956	is
O	1957	1967	considered
O	1968	1969	a
O	1970	1980	modifiable
O	1981	1985	risk
O	1986	1992	factor
O	1993	1995	of
O	1996	2002	breast
O	2003	2016	tumorigenesis
O	2016	2017	,
O	2018	2025	further
O	2026	2033	studies
O	2034	2037	are
O	2038	2046	required
O	2047	2049	to
O	2050	2056	assess
O	2057	2064	whether
O	2065	2073	inositol
O	2074	2082	combined
O	2083	2087	with
O	2088	2093	alpha
O	2094	2100	lipoic
O	2101	2105	acid
O	2106	2109	can
O	2110	2112	be
O	2113	2125	administered
O	2126	2128	as
O	2129	2130	a
O	2131	2138	dietary
O	2139	2149	supplement
O	2150	2152	in
O	2153	2159	breast
O	2160	2166	cancer
O	2167	2174	primary
O	2175	2185	prevention
O	2185	2186	.

O	2187	2194	Current
O	2195	2205	Controlled
O	2206	2211	Trial
O	2212	2226	ISRCTN74096908
O	2226	2227	.
